• Genetic testing for patients at risk of hereditary breast and ovarian cancer.
    • DeTroye A, Gabbett K, Yi C, Judice M, Luu V, Nelson B, Gregory T.
    • JAAPA. 2022 Oct 1;35(10):48-52. doi: 10.1097/01.JAA.0000873796.81961.da.
    • Cancer screening and breast cancer family history in Spanish-speaking Hispanic/Latina women in California.
    • Tamayo LI, Perez F, Perez A, Hernandez M, Martinez A, Huang X, Zavala V, Ziv E, Neuhausen S, Carvajal-Carmona LG, Duron Y, Fejerman L.
    • Front Oncol. 2022 Sep 28;12:940162. doi: 10.3389/fonc.2022.940162.
    • Returning individual genomic results to population-based cohort study participants with BRCA1/2 pathogenic variants.
    • Ohneda K, Hamanaka Y, Kawame H, Fuse N, Nagami F, Suzuki Y, Yamaguchi-Kabata Y, Shimada M, Masamune A, Aoki Y, Ishida T, Yamamoto M.
    • Breast Cancer. 2022 Sep 26. doi: 10.1007/s12282-022-01404-7. Epub ahead of print.
    • Using Social Media to Facilitate Communication About Women's Testing: Tool Validation Study.
    • Coffin T, Bowen D, Lu K, Swisher EM, Rayes N, Norquist B, Blank SV, Levine DA, Bakkum-Gamez JN, Fleming GF, I Olopade O, Romero I, D'Andrea A, Nebgen DR, Peterson C, Munsell MF, Gavin K, Crase J, Polinsky D, Lechner R.
    • JMIR Form Res. 2022 Sep 26;6(9):e35035. doi: 10.2196/35035.

    Related:

    Identifier: NCT02993068: Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible). (ClinicalTrials.gov)

    • Novel germline mutations for active surveillance and imaging strategies in prostate cancer.
    • Mondschein R, Taylor R, Thorne H, Bolton D.
    • Curr Opin Urol. 2022 Sep 1;32(5):456-461. doi: 10.1097/MOU.0000000000001024. Epub 2022 Jul 18.
    • Review
    • Assessment of psychosocial difficulties by genetic clinicians and distress in women at high risk of breast cancer: a prospective study.
    • Brédart A, Kop JL, Tüchler A, De Pauw A, Cano A, Dick J, Rhiem K, Devilee P, Schmutzler R, Stoppa-Lyonnet D, Dolbeault S.
    • Eur J Hum Genet. 2022 Sep;30(9):1067-1075. doi: 10.1038/s41431-022-01096-9. Epub 2022 Apr 11.
    • Mainstream germline genetic testing for patients with epithelial ovarian cancer leads to higher testing rates and a reduction in genetics-related healthcare costs from a healthcare payer perspective.
    • Bokkers K, Frederix GWJ, Velthuizen ME, van der Aa M, Gerestein CG, van Dorst EBL, Lange JG, Louwers JA, Koole W, Zweemer RP, Ausems MGEM.
    • Gynecol Oncol. 2022 Aug 25:S0090-8258(22)00550-9. doi: 10.1016/j.ygyno.2022.08.011. Epub ahead of print. Epub ahead of print.
    • Myriad Genetics, Clarified Precision Medicine Team up on Molecular Tumor Board Service.
    • [No author given]
    • GenomeWeb. Disease Areas. Cancer. 2022 Aug 24.
    • GeneHome - a Novel Model to Deliver Care to Individuals with Genetic Predisposition to Cancer.
    • Nocera Zachariah N, Lee MC, Chang MD, Moore C, Wang X.
    • Cancer Control. 2022 Jan-Dec [First published 2022 Aug 17];29:10732748221109951. doi: 10.1177/10732748221109951.
    • Training promotores to lead virtual hereditary breast cancer education sessions for Spanish-speaking individuals of Latin American heritage in California.
    • Reyna M, Almeida R, Lopez-Macha A, Fuller S, Duron Y, Fejerman L.
    • BMC Womens Health. 2022 Aug 8;22(1):336. doi: 10.1186/s12905-022-01902-y.
    • Long-Term Adaptation Among Adolescent and Young Adult Children to Familial Cancer Risk.
    • McDonnell GA, Peshkin BN, DeMarco TA, Peterson SK, Arun BK, Miesfeldt S, O'Neill SC, Schneider K, Garber J, Isaacs C, Luta G, Tercyak KP.
    • Pediatrics. 2022 Aug 1;150(2):e2022056339. doi: 10.1542/peds.2022-056339.

    Related:

    Commentary:

    Breaking Down the Barriers of Hereditary Cancer Risk Disclosure in AYA.

    • Making BRCA1 genetic test reports easier to understand through user-centered design: A randomized trial.
    • Recchia G, Lawrence ACE, Capacchione L, Freeman ALJ.
    • Genet Med. 2022 Aug;24(8):1684-1696. doi: 10.1016/j.gim.2022.04.016. Epub 2022 May 6.
    • Practice guidelines for BRCA1/2 tumour testing in ovarian cancer.
    • Grafodatskaya D, O'Rielly DD, Bedard K, Butcher DT, Howlett CJ, Lytwyn A, McCready E, Parboosingh J, Spriggs EL, Vaags AK, Stockley TL.
    • J Med Genet. 2022 Aug;59(8):727-736. doi: 10.1136/jmedgenet-2021-108238. Epub 2022 Apr 7.
    • The increasing importance of pathology in modern clinical trial conduct: OlympiA as a case in point.
    • Kalinowski L, Viale G, Domchek S, Tutt A, Lucas PC, Lakhani SR.
    • Pathology. 2022 Aug;54(5):511-516. doi: 10.1016/j.pathol.2022.05.003. Epub 2022 Jun 29.
    • Genetic Testing and Its Clinical Application in Prostate Cancer Management: Consensus Statements from the Hong Kong Urological Association and Hong Kong Society of Uro-Oncology.
    • Chiu PKF, Lee EKC, Chan MTY, Chan WHC, Cheung MH, Lam MHC, Ma ESK, Poon DMC.
    • Front Oncol. 2022 Jul 18;12:962958. doi: 10.3389/fonc.2022.962958.
    • Stress, anxiety, and health-related quality of life in BRCA1/2-positive women with and without cancer: A comparison of four US female samples.
    • Dibble KE, Donorfio LKM, Britner PA, Bellizzi KM.
    • Gynecol Oncol Rep. 2022 Jun 20;42:101033. doi: 10.1016/j.gore.2022.101033.
    • Programmatic Efforts Increase Adoption of Genomic Precision Medicine in Cancer Care in a Community Cancer Center.
    • Darabi S, Braxton D, Homer J, Brodie T, Holnagel D, Eisenberg B, Demeure MJ.
    • JCO Precis Oncol. 2022 Jun;6:e2200090. doi: 10.1200/PO.22.00090.
    • Homologous Recombination Deficiency and Ovarian Cancer Treatment Decisions: Practical Implications for Pathologists for Tumor Typing and Reporting.
    • Rabban JT, Chen LM, Devine WP.
    • Surg Pathol Clin. 2022 Jun;15(2):219-234. doi: 10.1016/j.path.2022.02.003. Epub 2022 May 18.
    • Review
    • UC Davis Looks to Expand Genetic Breast Cancer Risk Education, Outreach for Hispanic Women.
    • Kanski A.
    • Precision Oncology News. Technology. 2022 May 19.
    • News
    • Differences in Willingness to Undergo BRCA1/2 Testing and Risk Reducing Surgery among the General Public, Cancer Patients, and Healthcare Professionals: A Large Population-Based Survey.
    • Chang YJ, Cho S, Joo J, Ryu KH, Lee S, Cho J, Lim MC, Jung SY, Han JH, Lee ES, Kong SY.
    • J Pers Med. 2022 May 18;12(5):818. doi: 10.3390/jpm12050818.
    • Healthcare professionals' perspectives on implementation of universal tumor DNA testing in ovarian cancer patients: multidisciplinary focus groups.
    • Witjes VM, Braspenning JCC, Hoogerbrugge N, Smolders YHCM, Hermkens DMA, Mourits MJE, Ligtenberg MJL, Ausems MGEM, de Hullu JA.
    • Fam Cancer. 2022 May 16. doi: 10.1007/s10689-022-00294-0. Epub ahead of print.
    • Investigating factors that influence genetic counselors' decisions to refer patients to mental health providers.
    • Hayes T, Cunningham M, Trepanier A.
    • J Genet Couns. 2022 Apr 23. doi: 10.1002/jgc4.1582. Epub ahead of print.
    • Psychological Determinants of Men's Adherence to Cascade Screening for BRCA1/2.
    • Ongaro G, Petrocchi S, Calvello M, Bonanni B, Feroce I, Pravettoni G.
    • Curr Oncol. 2022 Apr 2;29(4):2490-2503. doi: 10.3390/curroncol29040203.
    • Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer.
    • Slootbeek PHJ, Kloots ISH, Smits M, van Oort IM, Gerritsen WR, Schalken JA, Ligtenberg MJL, Grünberg K, Kroeze LI, Bloemendal HJ, Mehra N.
    • Br J Cancer. 2022 Apr;126(6):907-916. doi: 10.1038/s41416-021-01663-9. Epub 2021 Dec 15.
    • Helix: A Digital Tool to Address Provider Needs for Prostate Cancer Genetic Testing in Clinical Practice.
    • Giri VN, Walker A, Gross L, Trabulsi EJ, Lallas CD, Kelly WK, Gomella LG, Fischer C, Loeb S.
    • Clin Genitourin Cancer. 2022 Apr;20(2):e104-e113. doi: 10.1016/j.clgc.2021.11.009. Epub 2021 Nov 27.
    • Recommendations for diagnosing STIC: a systematic review and meta-analysis.
    • Bogaerts JMA, Steenbeek MP, van Bommel MHD, Bulten J, van der Laak JAWM, de Hullu JA, Simons M.
    • Virchows Arch. 2022 Apr;480(4):725-737. doi: 10.1007/s00428-021-03244-w. Epub 2021 Dec 1.
    • Therapeutic implications of germline vulnerabilities in DNA repair for precision oncology.
    • Shah SM, Demidova EV, Lesh RW, Hall MJ, Daly MB, Meyer JE, Edelman MJ, Arora S.
    • Cancer Treat Rev. 2022 Mar;104:102337. doi: 10.1016/j.ctrv.2021.102337. Epub 2022 Jan 5.
    • Real-world homologous recombination repair mutation testing in metastatic castration-resistant prostate cancer in the USA, Europe and Japan.
    • Leith A, Ribbands A, Kim J, Last M, Barlow S, Yang L, Ghate SR.
    • Future Oncol. 2022 Mar;18(8):937-951. doi: 10.2217/fon-2021-1113. Epub 2022 Jan 19.
    • Safety, Feasibility, and Merits of Longitudinal Molecular Testing of Multiple Metastatic Sites to Inform mTNBC Patient Treatment in the Intensive Trial of Omics in Cancer.
    • Burton KA, Mahen E, Konnick EQ, Blau S, Dorschner MO, Ramirez AB, Schmechel SC, Song C, Parulkar R, Parker S, Senecal FM, Pritchard CC, Mecham BH, Szeto C, Spilman P, Zhu J, Gadi VK, Ronen R, Stilwell J, Kaldjian E, Dutkowski J, Benz SC, Rabizadeh S, Soon-Shiong P, Blau CA.
    • JCO Precis Oncol. 2022 Mar;6:e2100280. doi: 10.1200/PO.21.00280.
    • Genetic Testing Challenges in Oncology: Muddled Reporting, Interpretation of PALB2 VUS.
    • Ray T.
    • Precision Oncology News. Cancer Specialties. 2022 Feb 23.
    • Stakeholder attitudes towards establishing a national genomics registry of inherited cancer predisposition: a qualitative study.
    • Meiser B, Monnik M, Austin R, Nichols C, Cops E, Salmon L, Spurdle AB, Macrae F, Taylor N, Pachter N, James P, Kaur R.
    • J Community Genet. 2022 Feb;13(1):59-73. doi: 10.1007/s12687-021-00559-8. Epub 2021 Nov 2.
    • Remote AI Supported E-Multidisciplinary Oncology Conference in Breast Cancer as a Technology and Method to Optimize Outcomes in the Peripheries.
    • Mammas CS, Mamma AS, Papaxoinis G, Georgiou I.
    • Stud Health Technol Inform. 2022 Jan 14;289:309-312. doi: 10.3233/SHTI210921.
    • Non-BRCA Early-Onset Breast Cancer in Young Women.
    • Gao Y, Samreen N, Heller SL.
    • Radiographics. 2022 Jan-Feb;42(1):5-22. doi: 10.1148/rg.210109.
    • Review

    Related:

    Commentary:

    Invited Commentary: The Challenges of Early-Onset Breast Cancer.

    • Updates on breast biomarkers.
    • Najjar S, Allison KH.
    • Virchows Arch. 2022 Jan;480(1):163-176. doi: 10.1007/s00428-022-03267-x. Epub 2022 Jan 14.
    • Review
    • Diagnostic histologique et moléculaire des cancers de l'ovaire - recommandations pour la pratique clinique Saint-Paul 2021: Histological and molecular diagnosis of ovarian.
    • Genestie C, Gladieff L, Frère-Belda ML, Lortholary A, Vaur D, Treilleux I, Lyonnet DS.
    • Bull Cancer. 2021 Dec;108(9S1):S33-S38. doi: 10.1016/S0007-4551(21)00585-3.
    • Guideline
    • Most Genetic Counselors Encounter Discrepant Variant Classifications, Must Work Out Interpretations.
    • Curtin C.
    • Precision Oncology News. Diagnostics. Molecular Diagnostics. 2021 Nov 19.
    • Press, Conference report

    Related:

    Original research:

    Closing the gap: Systematic integration of multiplexed functional data resolves variants of uncertain significance in BRCA1, TP53, and PTEN.

    • Challenges and Errors in Genetic Testing: The Fifth Case Series.
    • Farmer MB, Bonadies DC, Pederson HJ, Mraz KA, Whatley JW, Darnes DR, Denton JJ, De Rosa D, Heatherly A, Kenney J, Lane K, Paul D, Pelletier RC, Shannon K, Williams D, Matloff ET.
    • Cancer J. 2021 Nov-Dec 01;27(6):417-422. doi: 10.1097/PPO.0000000000000553.
    • Case series
    • Fragmented responsibility: views of Israeli HCPs regarding patient recontact following variant reclassification.
    • Fridman AL, Raz A, Timmermans S, Shkedi-Rafid S.
    • J Community Genet. 2021 Oct 5:1–6. doi: 10.1007/s12687-021-00556-x. Epub ahead of print.
    • Fertility Considerations for Reproductive-Aged Carriers of Deleterious BRCA Mutations: A Call for Early Intervention.
    • Fine E, Knoll MA, Maslow BL.
    • JCO Oncol Pract. 2021 Oct 4:OP2100389. doi: 10.1200/OP.21.00389. Epub ahead of print.
    • Genetic Testing Challenges in Oncology: BRCA1 Variant Downgraded After Risk-Reducing Surgery.
    • Ray T.
    • Precision Oncology News. Biomarkers. BRCA. 2021 Sep 29.
    • Maximizing cancer prevention through genetic navigation for Lynch syndrome detection in women with newly diagnosed endometrial and nonserous/nonmucinous epithelial ovarian cancer.
    • Kim SR, Tone A, Kim RH, Cesari M, Clarke BA, Eiriksson L, Hart TL, Aronson M, Holter S, Lytwyn A, Maganti M, Oldfield L, Gallinger S, Bernardini MQ, Oza AM, Djordjevic B, Lerner-Ellis J, Van de Laar E, Vicus D, Pugh TJ, Pollett A, Ferguson SE.
    • Cancer. 2021 Sep 1;127(17):3082-3091. doi: 10.1002/cncr.33625. Epub 2021 May 13.
    • The Distinct Performances of Ultrasound, Mammograms, and MRI in Detecting Breast Cancer in Patients With Germline Pathogenic Variants in Cancer Predisposition Genes.
    • Liu J, Wang X, Dong L, Huang X, Zhao H, Li J, Huang S, Yuan P, Wang W, Wang J, Xing Z, Jia Z, Ming Y, Li X, Qin L, Liu G, Wu J, Li Y, Zhang M, Feng K, Ying J, Wang X.
    • Front Oncol. 2021 Jul 13;11:710156. doi: 10.3389/fonc.2021.710156.
    • Development and pilot testing of a training for bilingual community education professionals about hereditary breast and ovarian cancer among Latinas: ÁRBOLES Familiares.
    • Vadaparampil ST, Moreno Botero L, Fuzzell L, Garcia J, Jandorf L, Hurtado-de-Mendoza A, Campos-Galvan C, Peshkin BN, Schwartz MD, Lopez K, Ricker C, Fiallos K, Quinn GP, Graves KD.
    • Transl Behav Med. 2021 Jul 13:ibab093. doi: 10.1093/tbm/ibab093. Epub ahead of print.
    • Pancreas in Hereditary Syndromes: Cross-sectional Imaging Spectrum.
    • Katabathina VS, Buddha S, Rajebi H, Shah JN, Morani AC, Lubner MG, Dasyam A, Nazarullah A, Menias CO, Prasad SR.
    • Radiographics. 2021 Jun 18:200164. doi: 10.1148/rg.2021200164. Epub ahead of print.
    • Community research collaboration to develop a promotores-based hereditary breast cancer education program for Spanish-speaking Latinas.
    • Almeida R, Lopez-Macha A, Dugatkin T, Joseph G, Duron Y, Hurtado de Mendoza A, D Graves K, Fejerman L.
    • Health Educ Res. 2021 Jun 11:cyab011. doi: 10.1093/her/cyab011. Epub ahead of print.
    • OHSU to Expand Tumor Board Program After Seeing Benefits in Breast Cancer Patients.
    • Kanski A.
    • Precision Oncology News. Disease Areas. 2021 May 24.
    • The role of the genetic testing industry in patient education of hereditary cancer: An observational study assessing the quality of patient education videos.
    • Greenberg DC, Kamara D, Tatsugawa Z, Mendoza M, Pineda E, Holschneider CH, Zakhour M.
    • Gynecol Oncol. 2021 May;161(2):516-520. doi: 10.1016/j.ygyno.2021.02.013. Epub 2021 Feb 19.
    • Current update on the molecular genetics and management of hereditary ovarian cancers: a primer for radiologists.
    • Itani M, Lalwani N, Ganeshan D, Zulfiqar M, Siegel C.
    • Abdom Radiol (NY). 2021 Apr 13. doi: 10.1007/s00261-020-02911-x. Epub ahead of print.
    • Review
    • Controversies in Hereditary Cancer Management.
    • AlHilli MM, Pederson HJ.
    • Obstet Gynecol. 2021 Apr 8. doi: 10.1097/AOG.0000000000004364. Epub ahead of print.
    • Initiatives to Scale Up and Expand Reach of Cancer Genomic Services Outside of Specialty Clinical Settings: A Systematic Review.
    • Guan Y, McBride CM, Rogers H, Zhao J, Allen CG, Escoffery C.
    • Am J Prev Med. 2021 Feb;60(2):e85-e94. doi: 10.1016/j.amepre.2020.08.029. Epub 2020 Nov 7.
    • Review
    • Implementation of a High-Risk Breast Clinic for Comprehensive Care of Women With Elevated Breast Cancer Risk Identified by Risk Assessment Models in the Community.
    • Laws A, Mulvey TM.
    • JCO Oncol Pract. 2021 Feb;17(2):e217-e225. doi: 10.1200/OP.20.00256. Epub 2020 Aug 21.
    • #TripleNegativeBreastCancer on Instagram.
    • Henderson A, Miller CA, Sutton AL, Guidry JPD.
    • Health Educ Behav. 2021 Jan 10:1090198120985450. doi: 10.1177/1090198120985450. Epub ahead of print.
    • Prognostic and predictive parameters in breast pathology: a pathologist's primer.
    • Allison KH.
    • Mod Pathol. 2021 Jan;34(Suppl 1):94-106. doi: 10.1038/s41379-020-00704-7. Epub 2020 Nov 5.
    • Radiologic-Histopathologic Correlation of Transvaginal US and Risk-reducing Salpingo-oophorectomy for Women at High Risk for Tubo-ovarian Carcinoma.
    • Sakala MD, Curci NE, Masch WR, Mendiratta-Lala M, Stein EB, Wasnik AP, Sciallis AP, Uppal S, Pearlman MD, Maturen KE.
    • Radiol Imaging Cancer. 2020 Nov 13;2(6):e190086. doi: 10.1148/rycan.2020190086.
    • Pathology of Hereditary Breast and Ovarian Cancer.
    • Hodgson A, Turashvili G.
    • Front Oncol. 2020 Sep 29;10:531790. doi: 10.3389/fonc.2020.531790.
    • Knowledge and practice regarding prostate cancer germline testing among urologists: Gaps to address for optimal implementation.
    • Loeb S, Byrne N, Walter D, Makarov DV, Wise DR, Becker D, Giri VN.
    • Cancer Treat Res Commun. 2020 Sep 28;25:100212. doi: 10.1016/j.ctarc.2020.100212. Epub ahead of print.
    • Web-based return of BRCA2 research results: one-year genetic counselling experience in Iceland.
    • Stefansdottir V, Thorolfsdottir E, Hognason HB, Patch C, van El C, Hentze S, Cordier C, Mendes Á, Jonsson JJ.
    • Eur J Hum Genet. 2020 Jun 10. doi: 10.1038/s41431-020-0665-1. Epub ahead of print.
    • Genetic Testing and Screening Recommendations for Patients with Hereditary Breast Cancer.
    • Bharucha PP, Chiu KE, François FM, Scott JL, Khorjekar GR, Tirada NP.
    • Radiographics. 2020 May 29:190181. doi: 10.1148/rg.2020190181. Epub ahead of print.
    • Review

    Related:

    Commentary:

    Invited Commentary: Breast Cancer Risk Assessment and Screening Strategies-What's New?

    • Q&A: ACMG Work Group Hoping to Spark Discussion on Reporting Germline Findings From Tumor Testing.
    • Ray T.
    • Precision Oncology News. 2020 May 21.
    • News

    Related:

    Guidelines:

    Points to consider for reporting of germline variation in patients undergoing tumor testing: a statement of the American College of Medical Genetics and Genomics (ACMG).

    • Positive impact of genetic counseling assistants on genetic counseling efficiency, patient volume, and cost in a cancer genetics clinic.
    • Hallquist MLG, Tricou EP, Hallquist MN, Savatt JM, Rocha H, Evans AE, Deckard N, Hu Y, Kirchner HL, Pervola J, Rahm AK, Rashkin M, Schmidlen TJ, Schwartz MLB, Williams JL, Williams MS, Buchanan AH.
    • Genet Med. 2020 Apr 30. doi: 10.1038/s41436-020-0797-2. Epub ahead of print.
    • Points to consider for reporting of germline variation in patients undergoing tumor testing: a statement of the American College of Medical Genetics and Genomics (ACMG).
    • Li MM, Chao E, Esplin ED, Miller DT, Nathanson KL, Plon SE, Scheuner MT, Stewart DR; ACMG Professional Practice and Guidelines Committee.
    • Genet Med. 2020 Apr 23. doi: 10.1038/s41436-020-0783-8. Epub ahead of print.

    Related:

    News, Interview: Q&A: ACMG Work Group Hoping to Spark Discussion on Reporting Germline Findings From Tumor Testing. (Precision Oncology News)

    • NCCN Guidelines® Insights - Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020
    • NCCN Faculty
    • National Comprehensive Cancer Network. Continuing Education. Opens 2020 Apr 10. Exp 2021 Apr 10.
    • Continuing Education course

    Related:

    Guidelines:

    NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020.

    • Facilitated referral pathway for genetic testing at the time of ovarian cancer diagnosis: uptake of genetic counseling and testing and impact on patient-reported stress, anxiety and depression.
    • Frey MK, Lee SS, Gerber D, Schwartz ZP, Martineau J, Lutz K, Reese E, Dalton E, Olsen A, Girdler J, Pothuri B, Boyd L, Curtin JP, Levine DA, Blank SV.
    • Gynecol Oncol. 2020 Apr;157(1):280-286. doi: 10.1016/j.ygyno.2020.01.007. Epub 2020 Feb 11.
    • [Hereditary breast carcinomas pathologist's perspective].
    • Vincent-Salomon A, Bataillon G, Djerroudi L.
    • Ann Pathol. 2020 Mar 30. pii: S0242-6498(20)30059-6. doi: 10.1016/j.annpat.2020.02.023. [Epub ahead of print]
    • Review, [Article in French]
    • Education on cancer risk assessment and genetic counseling to address cancer health disparities among racial/ethnic groups and rural populations: Implementing culturally tailored outreach through community health educators.
    • San Miguel-Majors SL, Whitaker DE, Davis BC, Bailey LO, Springfield SA.
    • J Genet Couns. 2020 Mar 21. doi: 10.1002/jgc4.1272. [Epub ahead of print]
    • [The pathology of hereditary ovarian tumors].
    • Pesce F, Devouassoux-Shisheboran M.
    • Ann Pathol. 2020 Mar 13. pii: S0242-6498(20)30051-1. doi: 10.1016/j.annpat.2020.02.015. [Epub ahead of print]
    • Review, [Article in French]
    • Differences in physician opinions about controversial issues surrounding contralateral prophylactic mastectomy (CPM): A survey of physicians from accredited breast centers in the United States.
    • Yao K, Bleicher R, Moran M, Chang C, Dietz J, Stearns V, Connolly J, Sarantou T, Kurtzman S; National Accreditation Program for Breast Centers Data Working Group.
    • Cancer Med. 2020 Mar 11. doi: 10.1002/cam4.2914. [Epub ahead of print]
    • Feasibility, patient compliance and acceptability of ovarian cancer surveillance using two serum biomarkers and Risk of Ovarian Cancer Algorithm compared to standard ultrasound and CA 125 among women with BRCA mutations.
    • Haque R, Skates SJ, Armstrong MA, Lentz SE, Anderson M, Jiang W, Alvarado MM, Chillemi G, Shaw SF, Kushi LH, Powell CB.
    • Gynecol Oncol. 2020 Mar 4. pii: S0090-8258(20)30164-5. doi: 10.1016/j.ygyno.2020.02.027. [Epub ahead of print]
    • When to break the news and whose responsibility is it? A cross-sectional qualitative study of health professionals' views regarding disclosure of BRCA genetic cancer risk.
    • Young AL, Butow PN, Tucker KM, Wakefield CE, Healey E, Williams R.
    • BMJ Open. 2020 Feb 25;10(2):e033127. doi: 10.1136/bmjopen-2019-033127.
    • Serous Tubal Intraepithelial Carcinoma: A Concise Review for the Practicing Pathologist and Clinician.
    • Bachert SE, McDowell A Jr, Piecoro D, Baldwin Branch L.
    • Diagnostics (Basel). 2020 Feb 13;10(2). pii: E102. doi: 10.3390/diagnostics10020102.
    • Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers. I. Molecular Biomarkers in Prostate Cancer.
    • Lotan TL, Tomlins SA, Bismar TA, Van der Kwast TH, Grignon D, Egevad L, Kristiansen G, Pritchard CC, Rubin MA, Bubendorf L.
    • Am J Surg Pathol. 2020 Feb 10. doi: 10.1097/PAS.0000000000001450. [Epub ahead of print]
    • Review
    • Despite Barriers, Labs Starting to Report Suspected Cancer Risk Mutations Seen in Tumor Testing.
    • Ray T.
    • GenomeWeb. 2020 Feb 6.
    • Health Care Provider Perceptions of Caring for Individuals with Inherited Pancreatic Cancer Risk.
    • Underhill ML, Pozzar R, Chung D, Sawhney M, Yurgelun M.
    • J Cancer Educ. 2020 Feb;35(1):194-203. doi: 10.1007/s13187-019-01623-1.
    • [Learning from My Experience: Outpatient Care for Cancer Multigene Genomic Testing].
    • Aimono E, Iguchi A, Mochida K, Imai M, Hayashi H, Nishihara H.
    • Yakugaku Zasshi. 2020;140(5):667-668. doi: 10.1248/yakushi.19-00217-4.
    • Conference abstract, [Article in Japanese]
    • [Our Treatment Strategy for Patients with Hereditary Breast Cancer Syndrome in Hamamatsu Medical Center].
    • Miyamoto Y, Tochikubo J, Hosokawa Y, Amano K.
    • Yakugaku Zasshi. 2020;140(5):669-671. doi: 10.1248/yakushi.19-00217-5.
    • Breast Cancer Screening in BRCA Mutation Carriers: Necessity of a Relevant Update of Mammographic Modalities.
    • Colin C, Doutriaux-Dumoulin I.
    • Radiology. 2019 Sep 3:191306. doi: 10.1148/radiol.2019191306. [Epub ahead of print]
    • Letter, Comment

    Related:

    Original research:

    BRCA Mutation Carriers: Breast and Ovarian Cancer Screening Guidelines and Imaging Considerations.

    • Who's on third? Regulation of third-party genetic interpretation services.
    • Guerrini CJ, Wagner JK, Nelson SC, Javitt GH, McGuire AL.
    • Genet Med. 2019 Aug 12. doi: 10.1038/s41436-019-0627-6. [Epub ahead of print]
    • Review
    • Participation in a Novel Trial Assessing Prophylactic Breast Irradiation: The Importance of Input from the Radiation Oncologist.
    • Evron E, Goldberg H, Ben-David MA, Corn BW.
    • Int J Radiat Oncol Biol Phys. 2019 Aug 10. pii: S0360-3016(19)33636-3. doi: 10.1016/j.ijrobp.2019.08.004. [Epub ahead of print]
    • Peritoneal involvement by salpingoliths clinical significance and cytological challenges of interpretation.
    • El Hussein S, Guerrero D, Khader SN.
    • Diagn Cytopathol. 2019 Aug 7. doi: 10.1002/dc.24299. [Epub ahead of print]
    • Case report
    • The implications of genetic testing on radiotherapy decisions: a guide for radiation oncologists.
    • Bergom C, West CM, Higginson DS, Abazeed ME, Arun B, Bentzen SM, Bernstein JL, Evans JD, Gerber NK, Kerns SL, Keen J, Litton JK, Reiner AS, Riaz N, Rosenstein BS, Sawakuchi GO, Shaitelman SF, Powell SN, Woodward WA.
    • Int J Radiat Oncol Biol Phys. 2019 Aug 2. pii: S0360-3016(19)33530-8. doi: 10.1016/j.ijrobp.2019.07.026. [Epub ahead of print]
    • Review
    • Strategies for Improving Access to Hereditary Cancer Testing: Recommendations from Stakeholders.
    • Ready K, Johansen Taber KA, Bonhomme N, Lichtenfeld JL.
    • Genet Med. 2019 Aug;21(8):1702-1704. doi: 10.1038/s41436-018-0430-9. Epub 2019 Jan 28.
    • From Targeting Somatic Mutations to Finding Inherited Cancer Predispositions: The Other Side of the Coin.
    • Pujol P, De La Motte Rouge T, Penault-Llorca F.
    • Diagnostics (Basel). 2019 Jul 26;9(3). pii: E83. doi: 10.3390/diagnostics9030083.
    • Adverse Events in Genetic Testing: The Fourth Case Series.
    • Farmer MB, Bonadies DC, Mahon SM, Baker MJ, Ghate SM, Munro C, Nagaraj CB, Besser AG, Bui K, Csuy CM, Kirkpatrick B, McCarty AJ, McQuaid SW, Sebastian J, Sternen DL, Walsh LK, Matloff ET.
    • Cancer J. 2019 Jul/Aug;25(4):231-236. doi: 10.1097/PPO.0000000000000391.
    • Case series
    • Developing a culturally targeted video to enhance the use of genetic counseling in Latina women at increased risk for hereditary breast and ovarian cancer.
    • Hurtado-de-Mendoza A, Graves KD, Gómez-Trillos S, Song M, Anderson L, Campos C, Carrera P, Ostrove N, Peshkin BN, Schwartz MD, Ficca N, Cupertino AP, Gonzalez N, Otero A, Huerta E, Sheppard VB.
    • J Community Genet. 2019 May 18. doi: 10.1007/s12687-019-00423-w. [Epub ahead of print]
    • BRCA Mutation Carriers: Breast and Ovarian Cancer Screening Guidelines and Imaging Considerations.
    • Elezaby M, Lees B, Maturen KE, Barroilhet L, Wisinski KB, Schrager S, Wilke LG, Sadowski E.
    • Radiology. 2019 Apr 30:181814. doi: 10.1148/radiol.2019181814. [Epub ahead of print]

    Related:

    Letter, Comment:

    Breast Cancer Screening in BRCA Mutation Carriers: Necessity of a Relevant Update of Mammographic Modalities.

    • An Alternate Diagnostic Algorithm for the Diagnosis of Intraepithelial Fallopian Tube Lesions.
    • Perrone ME, Reder NP, Agoff SN, Garcia RL, Agnew KJ, Norquist BM, Pennington KP, Swisher EM, Kilgore MR.
    • Int J Gynecol Pathol. 2019 Apr 24. doi: 10.1097/PGP.0000000000000604. [Epub ahead of print]
    • Provider's Perceptions of Barriers and Facilitators for Latinas to Participate in Genetic Cancer Risk Assessment for Hereditary Breast and Ovarian Cancer.
    • Hurtado-de-Mendoza A, Graves K, Gómez-Trillos S, Anderson L, Campos C, Evans C, Stearns S, Zhu Q, Gonzalez N, Sheppard VB.
    • Healthcare (Basel). 2018 Sep 17;6(3). pii: E116. doi: 10.3390/healthcare6030116.
    • Sporadic and Hereditary Breast Cancer Genetics.
    • Zehr KR.
    • Radiol Technol. 2018 Sep;90(1):51M-64M.
    • Review
    • Angelina's Impact: Advocates Share.
    • [No author given]
    • My Gene Counsel. 2018 May 14.
    • Processing of fallopian tube, ovary, and endometrial surgical pathology specimens: A survey of U.S. laboratory practices.
    • Samimi G, Trabert B, Duggan MA, Robinson JL, Coa KI, Waibel E, Garcia E, Minasian LM, Sherman ME.
    • Gynecol Oncol. 2018 Mar;148(3):515-520. doi: 10.1016/j.ygyno.2018.01.016.
    • Gynaecological neoplasms in common familial syndromes (Lynch and HBOC).
    • Bartosch C, Clarke B, Bosse T.
    • Pathology. 2018 Feb;50(2):222-237. doi: 10.1016/j.pathol.2017.10.010. Epub 2017 Dec 26.
    • Review
    • Uncommon hereditary gynaecological tumour syndromes: pathological features in tumours that may predict risk for a germline mutation.
    • Garg K, Karnezis AN, Rabban JT.
    • Pathology. 2018 Feb;50(2):238-256. doi: 10.1016/j.pathol.2017.10.009. Epub 2018 Jan 17.
    • Review
    • The roles of pathology in targeted therapy of women with gynecologic cancers.
    • Murali R, Grisham RN, Soslow RA.
    • Gynecol Oncol. 2017 Nov 23. pii: S0090-8258(17)31530-5. doi: 10.1016/j.ygyno.2017.11.020. [Epub ahead of print]
    • Review
    • Fertility and pregnancy issues in BRCA-mutated breast cancer patients.
    • Lambertini M, Goldrat O, Toss A, Azim HA Jr, Peccatori FA, Ignatiadis M, Del Mastro L, Demeestere I.
    • Cancer Treat Rev. 2017 Sep;59:61-70. doi: 10.1016/j.ctrv.2017.07.001. Epub 2017 Jul 14.
    • Review
    • Breast Health Services: Accuracy of Benefit Coverage Information in the Individual Insurance Marketplace.
    • Hamid MS, Kolenic GE, Dozier J, Dalton VK, Carlos RC.
    • J Am Coll Radiol. 2017 Apr;14(4):482-487.e5. doi: 10.1016/j.jacr.2016.12.002. Epub 2017 Feb 3.
    • Design and Feasibility of an Intervention to Support Cancer Genetic Counselees in Informing their At-Risk Relatives.
    • de Geus E, Eijzenga W, Menko FH, Sijmons RH, de Haes HC, Aalfs CM, Smets EM.
    • J Genet Couns. 2016 Dec;25(6):1179-1187. Epub 2016 Apr 22.

    Related:

    Webinar: June 2016 Webinar: Spreading the word: a review of two family communication intervention studies. (NSGC. Cancer SIG. Webinar Recordings. 2016 Jun 29.)

    • [BRCA1 and BRCA2 - pathologists starting kit].
    • Škapa P.
    • Cesk Patol. 2016 Fall;52(4):193-196.
    • New challenges for BRCA testing: a view from the diagnostic laboratory.
    • Wallace AJ.
    • Eur J Hum Genet. 2016 Sep;24 Suppl 1:S10-8. doi: 10.1038/ejhg.2016.94.
    • Molecular Testing in Breast Cancer: A Guide to Current Practices.
    • Hagemann IS.
    • Arch Pathol Lab Med. 2016 Aug;140(8):815-24. doi: 10.5858/arpa.2016-0051-RA.
    • Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients.
    • George A, Riddell D, Seal S, Talukdar S, Mahamdallie S, Ruark E, Cloke V, Slade I, Kemp Z, Gore M, Strydom A, Banerjee S, Hanson H, Rahman N.
    • Sci Rep. 2016 Jul 13;6:29506. doi: 10.1038/srep29506.

    Related:

    Comments on NSGC Discussion Forum Cancer SIG

    Subject: Are We Just A Bunch of Health Care Money-Wasters Who Are Indirectly Responsible For People Getting Preventable Cancers?

    News:

    Streamlined genetic testing pathway is developed for women with ovarian cancer.

    Press: Simplified the Process. (GenomeWeb)

    Press: All women with ovarian cancer should be offered genetic testing – so why aren’t they? (Science Blog)

    • June 2016 Webinar: Spreading the word: a review of two family communication intervention studies.
    • Ilana Solomon.
    • NSGC. Cancer SIG. Webinar Recordings. 2016 Jun 29.

    Related:

    Communicating genetic test results within the family: Is it lost in translation? A survey of relatives in the randomized six-step study.

    Design and Feasibility of an Intervention to Support Cancer Genetic Counselees in Informing their At-Risk Relatives.

    • Understanding the Needs of Young Women Regarding Breast Cancer Risk Assessment and Genetic Testing: Convergence and Divergence among Patient-Counselor Perceptions and the Promise of Peer Support.
    • Evans C, Hamilton RJ, Tercyak KP, Peshkin BN, Rabemananjara K, Isaacs C, O'Neill SC.
    • Healthcare (Basel). 2016 Jun 28;4(3). pii: E35. doi: 10.3390/healthcare4030035.
    • Reproductive Endocrinologists' Utilization of Genetic Counselors for Oncofertility and Preimplantation Genetic Diagnosis (PGD) Treatment of BRCA1/2 Mutation Carriers.
    • Goetsch AL, Wicklund C, Clayman ML, Woodruff TK.
    • J Genet Couns. 2016 Jun;25(3):561-71. doi: 10.1007/s10897-015-9908-7. Epub 2015 Nov 14.
    • Lynch Syndrome: Female Genital Tract Cancer Diagnosis and Screening.
    • Mills AM, Longacre TA.
    • Surg Pathol Clin. 2016 Jun;9(2):201-14. doi: 10.1016/j.path.2016.01.004. Epub 2016 Apr 12.
    • Review
    • Beyond BRCA: A Pilot Program to Assess and Improve Knowledge of Pharmacogenomic Testing Among Advanced Practitioners in a Breast Cancer Treatment Setting.
    • Hoffman SL, Reid Kaufman RR, Ferrari S, Alexander SA, Rosenzweig MQ, Wesmiller SW.
    • J Adv Pract Oncol. 2016 May-Jun;7(4):382-389. Epub 2016 May 1.
    • Can the breast screening appointment be used to provide risk assessment and prevention advice?
    • Evans DG, Howell A.
    • Breast Cancer Res. 2015 Jul 9;17(1):84. doi: 10.1186/s13058-015-0595-y.
    • Are Women Willing to Change Breast Cancer Screening Guidelines?
    • Cohn W, Novicoff W, Dean MM, Guterbock T, Rexrode D, Eggleston C, Harvey J, Knaus W.
    • Cancer Epidemiol Biomarkers Prev. 2015 Apr;24(4):765. ASPO 39th Annual Meeting Abstracts. doi: 10.1158/1055-9965.EPI-15-0116.
    • Conference abstract
    • Molecular testing for the BRCA1 and BRCA2 Ashkenazi Jewish founder mutations: a report on the College of American Pathologists proficiency testing surveys.
    • Tafe LJ, Datto MB, Palomaki GE, Lacbawan FL.
    • Genet Med. 2015 Jan;17(1):58-62. doi: 10.1038/gim.2014.77. Epub 2014 Jun 19.
    • Implementing a screening tool for identifying patients at risk for hereditary breast and ovarian cancer: a statewide initiative.
    • Brannon Traxler L, Martin ML, Kerber AS, Bellcross CA, Crane BE, Green V, Matthews R, Paris NM, Gabram SG.
    • Ann Surg Oncol. 2014 Oct;21(10):3342-7. doi: 10.1245/s10434-014-3921-1. Epub 2014 Jul 22.

    Related:

    Comments from NSGC Discussion Forum Cancer SIG

    Subject: Article Request

    • From the set-up of a screening program of breast cancer patients to the identification of the first BRCA mutation in the DR Congo.
    • Luyeye Mvila G, Postema S, Marchal G, Van Limbergen E, Verdonck F, Matthijs G, Devriendt K, Michils G, Van Ongeval C.
    • BMC Public Health. 2014 Jul 28;14:759. doi: 10.1186/1471-2458-14-759.
    • Which factors predict proposal and uptake of psychological counselling after BRCA1/2 test result disclosure?
    • Maheu C, Bouhnik AD, Nogues C, Mouret-Fourme E, Stoppa-Lyonnet D, Lasset C, Berthet P, Fricker JP, Caron O, Luporsi E, Gladieff L, Julian-Reynier C.
    • Psychooncology. 2014 Apr;23(4):420-7. doi: 10.1002/pon.3435. Epub 2013 Oct 11.
    • Clinical cancer genetics. Part 2: Breast.
    • Pollock J, Welsh JS.
    • Am J Clin Oncol. 2014 Feb;37(1):86-9. doi: 10.1097/COC.0b013e31823fe657.
    • Review
    • The importance of understanding the psychological meaning of Angelina Jolie's surgery.
    • Goin MK.
    • J Psychiatr Pract. 2014 Jan;20(1):61-2. doi: 10.1097/01.pra.0000442939.69198.0c.
    • Survey on knowledge, attitudes, and training needs of italian residents on genetic tests for hereditary breast and colorectal cancer.
    • Panic N, Leoncini E, Di Giannantonio P, Simone B, Silenzi A, Ferriero AM, Falvo R, Silvestrini G, Cadeddu C, Marzuillo C, De Vito C, Ricciardi W, Villari , Boccia S.
    • Biomed Res Int. 2014;2014:418416. doi: 10.1155/2014/418416. Epub 2014 Jun 23.
    • Mammography techs ordering their own genetic testing? It appears our suspicion was correct.
    • [No author given]
    • Yale Cancer Genetic Counseling. 2013 Oct 2.
    • The counselees' self-reported request for psychological help in genetic counseling for hereditary breast/ovarian cancer: not only psychopathology matters.
    • Vos J, van Asperen CJ, Oosterwijk JC, Menko FH, Collee MJ, Garcia EG, Tibben A.
    • Psychooncology. 2013 Apr;22(4):902-10. doi: 10.1002/pon.3081. Epub 2012 Jun 27.
    • Grace Rock's consent.
    • Ross TS.
    • Endocr Relat Cancer. 2012 Jul 22;19(4):C29-31. doi: 10.1530/ERC-12-0186. Print 2012 Aug.
    • Attitudes to reproductive genetic testing in women who had a positive BRCA test before having children: a qualitative analysis.
    • Ormondroyd E, Donnelly L, Moynihan C, Savona C, Bancroft E, Evans DG, Eeles R, Lavery S, Watson M.
    • Eur J Hum Genet. 2012 Jan;20(1):4-10. doi: 10.1038/ejhg.2011.146. Epub 2011 Aug 3.